Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. (IBIO) is a biotechnology innovator providing end-to-end CDMO services and AI-driven solutions for biotherapeutics development. This page serves as the definitive source for all official company announcements, regulatory filings, and operational updates.
Investors and industry observers will find timely access to earnings reports, strategic partnerships, regulatory milestones, and technology advancements related to iBio's vaccine development and precision antibody platforms. Our curated feed ensures transparent tracking of the company's progress in accelerating biopharmaceutical production from discovery to commercialization.
All content is sourced directly from iBio's corporate communications, maintaining factual accuracy and compliance with financial disclosure standards. Bookmark this page for efficient monitoring of IBIO's developments in artificial intelligence applications for drug discovery, manufacturing expansions, and clinical trial updates.
iBio (NASDAQ: IBIO) has announced a licensing agreement with AstralBio for a preclinical first-in-class antibody targeting Activin E, discovered using iBio's Machine-Learning Antibody Engine. The antibody shows promise in inducing fat-selective weight loss and protecting against obesity and cardiometabolic disease.
Preclinical studies demonstrated strong antibody binding, inhibition of Activin E signaling, and fat-specific weight loss in an obese rodent model. The antibody represents the first functional inhibitor of Activin E, a genetically validated therapeutic target important for energy balance and fat distribution regulation.
Under the agreement terms, AstralBio provided iBio a $750,000 credit toward the option fee and will be eligible for development and commercialization milestone payments up to $28 million, plus low to mid-single-digit sublicense fees. Additionally, iBio amended its collaboration with AstralBio to add a fifth target for cardiometabolic disease treatment.
iBio (NASDAQ: IBIO) has announced promising data for its lead asset IBIO-600, a novel long-acting anti-myostatin antibody. In non-human primate studies, IBIO-600 demonstrated a potential human half-life of 57-130 days, suggesting possible dosing schedules of once every 3-6 months.
The exploratory study in obese and elderly non-human primates showed dose-dependent increases in lean mass and reductions in fat mass. At 8 weeks, low-dose subjects (5 mg/kg) showed a 3.1% increase in lean mass, while high-dose subjects (50 mg/kg) demonstrated a 5.1% increase.
Additionally, iBio reported interim data for their first-in-class Activin E antibody. In combination with semaglutide, it enhanced total weight loss by an additional 9% beyond GLP-1 therapy alone, achieving 34% overall weight reduction and 72% body fat reduction. The company remains on track for IBIO-600's regulatory submission in Q1 2026.
iBio (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, announced its approval for listing on the Nasdaq Capital Market. The company will transfer its stock exchange listing from NYSE American to Nasdaq, with trading expected to begin on March 4, 2025, maintaining its "IBIO" symbol. Trading on NYSE American will continue until market close on March 3, 2025.
CEO and Chief Scientific Officer Martin Brenner expressed optimism about joining the Nasdaq community of biotech companies, anticipating improved stock visibility, enhanced trading liquidity, and greater exposure to institutional investors.
iBio (NYSEA:IBIO) has reported its fiscal Q2 2025 financial results and corporate updates. The company recorded revenue of $0.2 million and a net loss of $4.4 million ($0.48 per share) for the quarter ended December 31, 2024. R&D and G&A expenses totaled $4.6 million, showing a 3% increase from the previous year.
Key developments include the discovery of a novel Activin E antibody in collaboration with AstralBio, the in-licensing of IBIO-600 (a long-acting anti-myostatin antibody), and the initiation of a bispecific antibody program targeting myostatin/activin A. The company strengthened its Board with the appointments of David Arkowitz and António Parada, and extended its cash runway through a private placement with Board members and Officers.
As of December 31, 2024, the company's cash position stood at $7.2 million, including $0.2 million in restricted cash.
iBio (NYSEA: IBIO) has secured over $650,000 through a private placement offering from its Board of Directors and Officers. The investment demonstrates internal confidence in the company's strategy as a clinical-stage biotech focused on developing therapeutics for cardiometabolic diseases and obesity.
The company is developing breakthrough antibody treatments designed to promote healthy weight loss while preserving and promoting muscle mass, and preventing weight regain. These therapeutics are being developed using iBio's machine-learning-based drug discovery platform, with a focus on high developability and extended half-life to potentially reduce dosing frequency compared to current obesity treatments.
iBio (NYSEA: IBIO) and AstralBio have announced the development of a novel antibody that inhibits Activin E, marking a significant breakthrough in treating cardiometabolic disorders and obesity. Using iBio's patented Machine-Learning Antibody Engine, the companies overcame the challenge of targeting Activin E, which is traditionally difficult to produce outside the human body.
The developed antibody demonstrates sub-nanomolar kinetics and complete blockade of Activin E-mediated signaling in human adipocytes. Research indicates that individuals with protective loss-of-function mutation in the INHBE gene show improved cardiometabolic profiles, including reduced abdominal fat and lower risk of type 2 diabetes.
Under the collaboration terms, AstralBio has licensed iBio's Drug Discovery Platform for four cardiometabolic disease targets, while iBio maintains options on three targets from AstralBio. This achievement follows their recent developments in myostatin and Activin A targeting programs.
iBio has expanded its cardiometabolic and obesity program by in-licensing an anti-myostatin antibody (IBIO-600) from AstralBio for $750,000 in common stock, with potential milestone payments up to $28 million. The antibody was discovered using iBio's proprietary technology and is designed for subcutaneous administration with extended half-life potential.
The company also launched a new bispecific antibody program targeting myostatin/activin A for obesity and cardiometabolic disorders treatment. In preclinical studies, IBIO-600 showed potent myostatin inhibition in human muscle cells and demonstrated 10-fold higher FcRn receptor binding affinity than normal IgG, suggesting potential for reduced dosing frequency. First data from non-human primate studies are expected in early 2025, with clinical investigations planned for 2026.
iBio (NYSEA:IBIO) has appointed two new independent directors to its Board: David Arkowitz and António Parada. Arkowitz, currently CFO at Alkeus Pharmaceuticals, brings extensive financial and operational experience, while Parada, Founder and CEO of FairJourney Biologics, contributes expertise in antibody drug discovery. The appointments align with iBio's vision of becoming a next-generation antibody discovery and development company focused on cardiometabolic diseases and oncology. General Tom Hill will be departing the board after sixteen years of service.
iBio reported fiscal Q1 2025 results with key developments in its myostatin program. The company has begun dosing in non-human primate studies, collaborating with AstralBio for cardiometabolic disease and obesity treatments. Financial highlights include: no revenue reported, R&D and G&A expenses decreased 20% to $4.1 million, net loss of $4.0 million ($0.46 per share), and cash position of $11.3 million. The company appointed Kristi Sarno as SVP of Business Development and expects early study readouts in early 2025.
iBio and AstralBio have provided an update on their joint myostatin program for cardiometabolic disease and obesity. The companies have identified a lead molecule with potential for extended half-life and subcutaneous dosing. This molecule is designed to treat muscle wasting and obesity, with plans to advance into non-cGMP in vivo studies in rodents and non-human primates. Potential early readouts from NHP studies are expected in early 2025.
The collaboration aims to develop a best-in-class myostatin inhibitor focusing on high potency and extended half-life. iBio has the option to license three cardiometabolic targets from AstralBio and aims to file an IND application by the end of 2025 if it exercises the option for the myostatin program.
